Afya (NASDAQ:AFYA) Sees Unusually-High Trading Volume – Here’s Why

by · The Markets Daily

Shares of Afya Limited (NASDAQ:AFYA – Get Free Report) saw unusually-high trading volume on Thursday . Approximately 115,736 shares changed hands during mid-day trading, a decline of 8% from the previous session’s volume of 126,422 shares.The stock last traded at $13.52 and had previously closed at $13.58.

Key Afya News

Here are the key news stories impacting Afya this week:

  • Positive Sentiment: Strategic merger creates a larger education platform. Afya and Yduqs signed a binding agreement to combine their Brazilian higher-education operations, creating a company valued at approximately R$9 billion. The transaction would broaden Afya’s scale beyond medical education and strengthen its position in Brazil. Afya and Yduqs merger announcement
  • Positive Sentiment: Potential cost and operating synergies. JPMorgan reportedly sees as much as R$2.8 billion in potential synergies, offering a possible boost to earnings and cash generation if the companies successfully integrate their operations. Afya is expected to own approximately 69.3% of the combined company, giving it majority control. JPMorgan merger scenarios
  • Positive Sentiment: Shareholder distribution included in the deal terms. Reports indicate the transaction includes a share exchange and approximately R$750 million in dividends, which could provide near-term value to shareholders. Merger share exchange and dividends
  • Neutral Sentiment: Potential Nasdaq listing change. Reports suggest the combined structure could result in Afya leaving Nasdaq while Yduqs remains listed in Brazil. This may alter the company’s investor base, liquidity and valuation framework, although the final listing arrangements remain important details for investors. Potential Afya Nasdaq delisting
  • Negative Sentiment: Analyst-screen pressure adds to caution. Zacks added AFYA to its Rank #5 “Strong Sell” list, potentially weighing on sentiment. Investors may also remain concerned about regulatory approvals, integration costs, transaction dilution and whether the projected synergies can be realized. Zacks Strong Sell list

Analysts Set New Price Targets

Several research analysts have commented on AFYA shares. Bradesco Corretora raised Afya to an “outperform” rating and set a $17.00 price target on the stock in a research report on Thursday. Weiss Ratings cut Afya from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Bank of America restated a “neutral” rating on shares of Afya in a research note on Thursday, June 11th. Zacks Research lowered shares of Afya from a “hold” rating to a “strong sell” rating in a research report on Friday, August 21st. Finally, Wall Street Zen upgraded shares of Afya from a “hold” rating to a “buy” rating in a research note on Saturday, September 5th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.75.

Check Out Our Latest Analysis on Afya

Afya Stock Performance

The firm has a fifty day simple moving average of $14.02 and a 200 day simple moving average of $14.34. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.39. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of 8.20, a PEG ratio of 1.51 and a beta of 0.35.

Afya (NASDAQ:AFYA – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.03. Afya had a net margin of 20.55% and a return on equity of 17.58%. The firm had revenue of $187.80 million for the quarter, compared to analyst estimates of $189.62 million. As a group, sell-side analysts expect that Afya Limited will post 1.86 earnings per share for the current year.

Insider Activity at Afya

In other news, VP Lélio de Souza, Jr. sold 41,541 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $15.00, for a total transaction of $623,115.00. Following the transaction, the vice president directly owned 36,204 shares in the company, valued at approximately $543,060. This represents a 53.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Gomiero Mirella Basolli sold 10,000 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $14.80, for a total value of $148,000.00. Following the completion of the transaction, the vice president owned 34,530 shares in the company, valued at $511,044. The trade was a 22.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,745 shares of company stock worth $1,314,175 over the last three months. 0.80% of the stock is owned by company insiders.

Institutional Trading of Afya

Institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new stake in Afya in the second quarter valued at about $67,000. Engineers Gate Manager LP acquired a new position in Afya in the second quarter valued at about $325,000. Banco BTG Pactual S.A. bought a new position in Afya during the fourth quarter worth about $462,000. Finally, Swedbank AB boosted its holdings in Afya by 170.3% during the fourth quarter. Swedbank AB now owns 189,200 shares of the company’s stock worth $2,916,000 after buying an additional 119,200 shares during the last quarter. Institutional investors and hedge funds own 88.02% of the company’s stock.

About Afya

(Get Free Report)

Afya Limited is a Brazilian medical education and technology company that operates an integrated platform for physicians and medical students. The company provides education and professional development throughout the medical career cycle, from undergraduate training and residency preparation to continuing medical education and specialization programs.

Afya’s offerings include medical schools, preparatory courses, postgraduate and continuing education programs, digital learning tools, and clinical practice technologies.

Further Reading